000			01797 a2200469 4500
005			20250515092545.0
264		0	_c20080229
008			200802s 0 0 eng d
022			_a1053-8569
024	7		_a10.1002/pds.1508 _2doi
040			_aNLM _beng _cNLM
100	1		_aSukel, Myrthe P P
245	0	0	_aLarge-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. _h[electronic resource]
260			_bPharmacoepidemiology and drug safety _cJan 2008
300			_a9-19 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aCardiovascular Diseases _xprevention & control
650	0	4	_aCohort Studies
650	0	4	_aCyclooxygenase 2 Inhibitors _xadministration & dosage
650	0	4	_aDatabases, Factual
650	0	4	_aDrug Prescriptions _xstatistics & numerical data
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDrug Utilization Review
650	0	4	_aDrug and Narcotic Control
650	0	4	_aFemale
650	0	4	_aGastrointestinal Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aLactones _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPractice Patterns, Physicians' _xstatistics & numerical data
650	0	4	_aProton Pump Inhibitors
650	0	4	_aSulfones _xadministration & dosage
700	1		_avan der Linden, Michiel W
700	1		_aChen, Connie
700	1		_aErkens, Joëlle A
700	1		_aHerings, Ron M C
773	0		_tPharmacoepidemiology and drug safety _gvol. 17 _gno. 1 _gp. 9-19
856	4	0	_uhttps://doi.org/10.1002/pds.1508 _zAvailable from publisher's website
999			_c17482374 _d17482374